<DOC>
	<DOCNO>NCT00875693</DOCNO>
	<brief_summary>This open-label Phase I study design determine maximum tolerate dose ( MTD ) CPX-351 follow reduce intensity condition regimen incorporate dose-escalation schedule sequentially enroll 6 dosing cohort . After determination MTD , investigator reserve option enroll 10 additional subject expand safety cohort ( ) MTD . Refractory relapse AML patient meet standard institutional criterion undergo sequential induction/reduced intensity condition allogeneic transplant offer transplant relate unrelated donor ( full match 1 antigen mismatch ) . Cord blood transplant use study .</brief_summary>
	<brief_title>A Novel Sequential Treatment Salvage Reduced Intensity Conditioning ( RIC ) Chemotherapy Allogeneic Stem-Cell Transplantation ( SCT ) Primary Refractory Relapsed Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Patients include , fulfill least one follow criterion define refractory relapse AML accord previously establish criterion 13 : ( 1 ) Primary induction failure ( PIF ) â‰¥ 2 cycle chemotherapy . ( 2 ) First relapse . ( 3 ) Relapse refractory salvage chemotherapy ( 4 ) Second subsequent relapse . 2 . Patients MDS , either RAEB I RAEB II 3 . Age 18 70 year old . 4 . Patients must Karnofsky Performance Status &gt; 70 . 5 . Each patient must willing participate research subject must sign informed consent form . 6 . If patient history prior malignancy , must without evidence disease prior malignancy least 2 year eligible transplant protocol . This exclude skin cancer may excise within 2 year period . 7 . Patients must adequate physical function measure : 1 . Cardiac : asymptomatic symptomatic LVEF rest must &gt; 50 % must improve exercise . 2 . Hepatic : &lt; 3x ULN ALT &lt; 1.5 total serum bilirubin , unless liver involved disease congenital benign hyperbilirubinemia . 3 . Renal : serum creatinine within normal range age serum creatinine outside normal range , CrCl &gt; 60ml/min . 4 . Pulmonary : asymptomatic symptomatic , DLCO &gt; 45 % predict ( correct hemoglobin ) 1 . Impaired renal function measure calculated creatinine clearance le 60 ml/min . 2 . Impaired hepatic function define bilirubin great 1.5 x upper limit normal ALT AST great 3 x normal . 3 . Serious active uncontrolled infection ( Infections control patient afebrile hemodynamically stable 72 hour ) medical condition . 4 . Women pregnant breast feeding . Women childbearing age must use adequate contraception negative pregnancy test . 5 . Impaired pulmonary function DLCO le 45 % predict . 6 . Impaired cardiac function ejection fraction le 50 % predict echocardiogram MUGA . 7 . Prior daunorubicin therapy cumulative dose 368 mg/m2 equivalent . The anthracycline agent commonly use treat myeloid malignancy doxorubicin , idarubicin mitoxantron . For example , patient receive 7 + 3 ( daunorubicin 180 mg/m2 ) induction MEC ( mitoxantrone 48 mg/m2 ) salvage . The cumulative daunorubicin equivalent 180 + ( 48x2 ) = 278 mg/m2 . 8 . Other systemic anticancer therapy ongoing toxicity therapy . 9 . Patients history and/or current evidence myocardial impairment ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) , result heart failure New York Heart Association Class III IV stag . 10 . Patients Wilson disease Curelated disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>leukemia</keyword>
	<keyword>MDS</keyword>
</DOC>